60 Degrees Pharmaceuticals (NASDAQ:SXTP) Announces Earnings Results

60 Degrees Pharmaceuticals (NASDAQ:SXTP) issued its quarterly earnings results on Wednesday. The company reported ($4.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44), Yahoo Finance reports. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.11 million.

60 Degrees Pharmaceuticals Trading Down 5.5 %

SXTP stock opened at $1.56 on Friday. The company has a market capitalization of $1.59 million and a P/E ratio of -1.50. 60 Degrees Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $22.32. The business has a 50 day simple moving average of $0.35 and a 200-day simple moving average of $0.30.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Thursday.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.